SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its position in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 90.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,912 shares of the company's stock after selling 293,809 shares during the quarter. Federated Hermes Inc. owned 0.08% of SI-BONE worth $670,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of SIBN. Zurcher Kantonalbank Zurich Cantonalbank grew its position in SI-BONE by 14.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,541 shares of the company's stock worth $179,000 after acquiring an additional 1,106 shares in the last quarter. VELA Investment Management LLC lifted its stake in shares of SI-BONE by 63.5% in the 4th quarter. VELA Investment Management LLC now owns 61,577 shares of the company's stock valued at $1,293,000 after purchasing an additional 23,914 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of SI-BONE by 7.7% in the 4th quarter. Arizona State Retirement System now owns 10,675 shares of the company's stock worth $224,000 after purchasing an additional 762 shares during the period. HighMark Wealth Management LLC bought a new position in shares of SI-BONE during the 4th quarter valued at approximately $399,000. Finally, Assenagon Asset Management S.A. raised its holdings in SI-BONE by 92.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 419,940 shares of the company's stock valued at $8,815,000 after buying an additional 201,615 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SIBN has been the topic of a number of analyst reports. Piper Sandler started coverage on shares of SI-BONE in a research report on Thursday, March 28th. They set an "overweight" rating and a $25.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 27th. Morgan Stanley raised their price target on SI-BONE from $25.00 to $26.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. Truist Financial reaffirmed a "buy" rating and issued a $24.00 price objective (down previously from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $27.00 target price on shares of SI-BONE in a research report on Wednesday, April 3rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $26.67.

SI-BONE Stock Down 2.8 %

Shares of SI-BONE stock traded down $0.41 during trading on Friday, hitting $14.20. 396,112 shares of the stock traded hands, compared to its average volume of 428,375. The company has a current ratio of 9.01, a quick ratio of 8.15 and a debt-to-equity ratio of 0.21. The stock's fifty day simple moving average is $16.11 and its 200 day simple moving average is $18.05. The firm has a market cap of $585.04 million, a P/E ratio of -12.82 and a beta of 1.24. SI-BONE, Inc. has a 52-week low of $14.07 and a 52-week high of $29.51.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, February 26th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. The business had revenue of $38.86 million for the quarter, compared to the consensus estimate of $38.60 million. On average, equities analysts predict that SI-BONE, Inc. will post -0.98 earnings per share for the current fiscal year.

Insider Activity at SI-BONE

In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total transaction of $37,466.25. Following the sale, the chief financial officer now owns 205,516 shares of the company's stock, valued at approximately $3,175,222.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $15.45, for a total transaction of $37,466.25. Following the completion of the sale, the chief financial officer now directly owns 205,516 shares of the company's stock, valued at $3,175,222.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mika Nishimura sold 2,500 shares of SI-BONE stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $16.22, for a total transaction of $40,550.00. Following the completion of the transaction, the director now directly owns 19,350 shares in the company, valued at approximately $313,857. The disclosure for this sale can be found here. Insiders have sold a total of 11,905 shares of company stock valued at $190,273 over the last ninety days. 5.40% of the stock is owned by company insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.